Latest Human Genome Sciences Stories
ROCKVILLE, Md., Aug. 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
ROCKVILLE, Md., July 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the pricing of its underwritten public offering of 23,215,000 newly issued shares of its common stock at a price to the public of $14.00 per share.
ROCKVILLE, Md., July 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 18,000,000 shares of its common stock.
After a 50-year drought in Lupus treatments, scientists announce positive results from a clinical trial for a new drug.
ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S.
The experimental drug Benlysta shows great promise in treating lupus and could be available to the public late next year, its Maryland-based developer said. Benlysta is the first promising new treatment for lupus, an autoimmune disease, in nearly 50 years, researchers at Human Genome Sciences, of Rockville, said. Pending the results of another round of tests, the company plans to file for U.S.
Human Genome Sciences Inc reported on Monday that a late-stage clinical trial of its experimental lupus drug Benlysta had shown success in reducing symptoms of the disease.
First Phase 3 Lupus Drug Trial in Decades to Show Effectiveness NEW YORK, July 20 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus."We are very hopeful that we now are strongly on our way to the first new treatment for lupus in 50 years,"...
BENLYSTA(TM) SUCCESSFUL IN FIRST OF TWO PIVOTAL CLINICAL TRIALSWASHINGTON, July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus.
- A trick or prank.